A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas

Journal of Neuro-Oncology

Volumn 125, Issue 1, 2015, Pages 191-195

  Odia, Yazmín ^a   Kreisl, Teri N ^a   Aregawi, Dawit ^b   Innis, Ellen K ^c   Fine, Howard A ^d  

^a NEUROLOGICAL INSTITUTE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Bortezomib; Glioblastoma; Glioma; Tamoxifen

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; CREATININE; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COUGHING; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MICTURITION DISORDER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; RECTUM HEMORRHAGE; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; URINARY FREQUENCY; VEIN THROMBOSIS; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; FOLLOW UP; GLIOMA; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TAMOXIFEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942990748     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1894-y     Document Type: Article

References (27)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncol 14(suppl 5):v1–v49
2. Louis D, Ohgaki H, Wiestler O et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109
3. Frankel SA, German WJ (1958) Glioblastoma multiforme. J Neurosurg 15(5):489–503
4. Pichlmeier U, Bink A, Schackert G, Stummer W (2008) Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro-Oncol 10(6):1025–1034
5. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572
6. Laperriere N, Zuraw L, Cairncross G (2002) Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64(3):259–273
7. Scott CB, Scarantino C, Urtasun R et al (1998) Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40(1):51–55
8. Tsao MN, Mehta MP, Whelan TJ et al (2005) The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 63(1):47–55
9. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
10. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507
11. De Graffenried LA, Chandrasekar B, Friedrichs WE et al (2004) NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 15(6):885–890
12. Hui A-M, Zhang W, Chen W et al (2004) Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in er-negative glioma cells. Cancer Res 64(24):9115–9123
13. Oida K, Matsuda A, Jung K et al (2014) Nuclear factor-kB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Sci Rep 4(4057):1–8
14. Zhou Y, Yau C, Gray JW et al (2007) Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7:59
15. Roccaro LM, Vacca A, Ribatti D (2006) Bortezomib in the treatment of cancer. Recent Pat Anti-Cancer Drug Discov 1(3):397–403
16. Williamson MJ, Silva MD, Terkelsen J et al (2009) The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol Cancer Ther 8(12):3234–3243
17. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972
18. Peng L, Ye X, Zhou Y, Zhang J, Zhao Q (2015) Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Support Care Cancer 17:1–12
19. Mastronardi L, Puzzilli F, Ruggeri A (1998) Tamoxifen as a potential treatment of glioma. Anticancer Drugs 9:581–586
20. Patel S, DiBiase S, Meisenberg B et al (2012) Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. Int J Radiat Oncol Biol Phys 82(2):739–742
21. Napolitano M, Keime-Guibert F, Monjour A et al (1999) Treatment of Supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study. J Neurooncol 45(3):229–235
22. Brandes AA, Ermani M, Turazzi S et al (1999) Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 17(2):645
23. Spence A, Peterson R, Scharnhorst J, Silbergeld D, Rostomily R (2004) Phase II study of concurrent continuous temozolomide (TMZ) and tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neurooncol 70(1):91–95
24. Tang P, Roldan G, Brasher PMA et al (2006) A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol 78(3):311–316
25. Robins HI, Won M, Seiferheld WF et al (2006) Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro-Oncol 8(1):47–52
26. Michalski A, Bouffet E, Taylor R et al (2010) The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. J Neurooncol 100(1):81–88
27. Trinh X, Sas L, Van Laere S et al (2012) A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. Oncol Rep 27(3):657–663